tiprankstipranks
Trending News
More News >

Xinhua Pharmaceutical Gains Approval for Marketing License Change

Story Highlights
Xinhua Pharmaceutical Gains Approval for Marketing License Change

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.

Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Epalrestat tablets. This approval is part of a broader agreement with Beijing Minkang Baicao Pharmaceutical Technology Company Limited, which involves the transfer of production technology and marketing authorization holder status for Mecobalamin tablets to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical industry.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production and marketing of prescription drugs. The company focuses on the development and commercialization of various pharmaceutical products, including Mecobalamin tablets.

YTD Price Performance: -3.10%

Average Trading Volume: 2,170,030

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.56B

Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1